No Data
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results From Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Assess Iopofosine I 131 in Mycoid Diseases
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Assess Iopofosine I 131 in Mycoid Diseases
Express News | Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Cellectar Biosciences Inc files for up to $300 million hybrid shelf — SEC filing
Cellectar Biosciences Inc files for up to $300 million hybrid shelf — SEC filing
Express News | Cellectar Biosciences Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing
Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline